ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Announcement, RFA On Drug Discovery Groups Coming

December 10, 1982

Roswell Park Instigators Find Improved Treatment For Bladder Cancer

May 23, 1975

Litton Awarded $342,618 For Frederick Fee

February 21, 1975

“Roller-Coaster Budget” For NIH Criticized On Capitol Hill; $1 Billion Cut By FY 2000?

March 17, 1995

$1.5 Million In Direct Costs Is Proposed Core Grant Requirement

July 12, 1991

In Brief: Holland Retires As Center Director, Replaced By NCI’s Aaronson; Lab Chiefs Leaving NCI

September 24, 1993